Bio-pharmaceutical industry

The Dalian Changxing Island Economic and Technological Development Zone capitalizes on its strategic location within the national petrochemical industrial base and provincial fine chemical industrial park to spearhead the establishment of a comprehensive biopharmaceutical industrial chain. This initiative actively promotes the development of characteristic Active Pharmaceutical Ingredients (APIs), with a particular focus on specific domains, such as small molecules, macromolecules, and polymers.

Changxing Island is strategically positioned to seize upon the favorable opportunity presented by the elevation of the Dalian International Life Science Corridor to a national strategic priority. Leveraging China-Japan cooperation as a starting point, the island is aligning itself with international standards such as RCEP (Regional Comprehensive Economic Partnership), ICH (The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use), and PIC/S (Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme).

Furthermore, the island is committed to propelling high-quality innovation in biopharmaceutical Contract Development and Manufacturing Organization (CDMO) services, while also catalyzing a 100-billion-yuan ($13.8 billion) biopharmaceutical industry with a 10-billion-yuan API industry. By pioneering a new frontier of open cooperation in Northeast China, specifically in the biopharmaceutical domain facing Northeast Asia, Changxing Island aims to position itself as a trailblazer in this rapidly evolving sector.

Source: Changxing Island Economic and Technological Development Zone